Compare Inovio Pharmaceuticals Inc (INO) vs J B Hunt Transport Services Inc (JBHT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs J B Hunt Transport Services Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M), while J B Hunt Transport Services Inc trades at $276.79 (market cap $24.92B). The key difference: J B Hunt Transport Services Inc is far larger — about 317.3× Inovio Pharmaceuticals Inc's market cap, and J B Hunt Transport Services Inc pays a 0.68% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | JBHT | |
|---|---|---|
Market Cap | $78.55M | $24.92B |
Sector | Health | Industrials |
52-Week High | $2.87 | $298.41 |
52-Week Low | $0.66 | $130.65 |
Enterprise Value | $49.56M | $26.06B |
Dividend Yield | — | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
JBHT trades at $275.5, up 3.52% today, with a bearish technical signal but strong analyst consensus. The company reported revenue of $12.0B in 2025, with net income of $598.28M and a 5.31% net margin. Recent earnings have consistently beaten estimates, and the company announced a $0.45 dividend payable in August 2026. Cash flow from operations remains robust at $1.68B in 2025, though net cash flow was slightly negative.
The outlook is positive with a consensus price target of $299.82, implying 8.8% upside. Risks include competitive pressures and macroeconomic volatility, but strong institutional ownership and a buy rating from 57.8% of analysts support a favorable view. The stock's valuation multiples are elevated, but earnings growth and intermodal demand recovery provide catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →
